Abstract: Objective To study the clinical features, effects of therapeutic regimen and prognosis of patents with mantle cell lymphoma (MCL). Methods Clinical data of 27 MCL patients admitted in Tianjin Medical University Cancer Institute & Hospital from January 2008 to December 2014 were retrospectively analyzed. Cox regression analysis was used to analyze influencing factors of prognosis of MCL. Results The median age was 68 years old for 27 patients, and the male-tofemale ratio was 4.4∶ 1. Ann Arbor staging showed that 25 cases were stage Ⅲ-Ⅳ(92.6%), 8 cases were heptosplenomegaly (29.6%), 7 cases showed extranodal involvement (25.9%). ECOG scoring showed that 4 cases with scores of 2-4 (14.8%), 8 cases were 0-3 (29.6%), 14 cases were 4-5 (51.9%) and 5 cases were 6-11 (18.5%). The Ki-67 index ≤30% was found in 9 cases (33.3%), and＞ 30% was found in 18 cases (67.7%). Patients with B symptom was found in 10 (37.0%). The elevated lactate dehydrogenase (LDH) was found in 17 cases (63.0%). The increased Beta 2- microglobulin was found in 8 cases (29.6%). Seven patients were found with bone marrow involvement. The total effective rate (ORR) was 81.8% in group with R-CHOP method, and the ORR was 68.8% in group with CHOP method. Multivariate analysis showed that age, LDH and Ki- 67 were independent factors influencing the prognosis of MCL (P＜ 0.05). Conclusion Most patients with MCL are found in advanced stage. Patients with age＞ 60 years, elevated LDH and Ki-67 index＞ 30% are with poor prognosis.

Key words: lymphoma, mantle- cell, L- lactate dehydrogenase, Ki- 67 antigen, lymphoma, prognosis, mantle cell lymphoma, MIPI score